Summary
81 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 131% a year over the last 3 years.
- It earns 65 USD a year on every 100 USD of invested capital.
- It holds more cash than debt: $631.1K against $353.2K.
- The share price is below the Bulios Fair Price.
What to watch
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 6.7 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 203% a year over 5 years. Over the last 3 years it grew by 803% a year. Earnings per share grew by 131% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 46 USD
- Sales and administration 27 USD
- Taxes and other 2.1 USD
- Net profit 11 USD
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 USD
Out of every 100 USD of revenue, 11 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Shipping and Handling 89%
- Other Revenue 11%
By region
The company reports no revenue by region.
Shipping and Handling brings in 89% of revenue.
Segments in detail